Initial human feasibility study of DC Ablation as a treatment for benign prostatic hyperplasia: 6 month follow-up data
- Resource Type
- Authors
- O. Storme; Claudia Ramis; Benjamin R. Fruland; Juan Cabezas; Kai Kroll; Thayne R. Larson
- Source
- 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.
- Subject
- Male
medicine.medical_specialty
Necrosis
medicine.medical_treatment
Prostatic Hyperplasia
Urology
Prostate
Lower urinary tract symptoms
Humans
Medicine
Electrodes
Aged
Aged, 80 and over
medicine.diagnostic_test
business.industry
Magnetic resonance imaging
Equipment Design
Middle Aged
Hyperplasia
Ablation
medicine.disease
Equipment Failure Analysis
Treatment Outcome
medicine.anatomical_structure
Coagulative necrosis
Tolerability
Catheter Ablation
Feasibility Studies
medicine.symptom
business
Follow-Up Studies
- Language
Direct current (DC) ablation is a novel non-thermal technology that causes focused coagulative necrosis in the lateral lobes of the prostate to treat benign prostatic hyperplasia (BPH). The necrosis is caused by a zone of non-physiologic pH which is created in a predictable pattern around each electrode in which a direct current is applied during treatment. The objective of this study was to optimize treatment parameters and assess treatment tolerability using transurethral DC ablation as an office-based treatment for BPH.